A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

NCT03563599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

Interventions

DRUG: Telacebec (Q203)
DRUG: Rifafour e-275

Sponsor

Qurient Co., Ltd.